Student or educator? Sign up with your school email and get 6 months of Pro free.
Cited by 204

The DOI matches its Crossref record; 14 of the 14 references it cites were found in a registry or an index.

The head and neck cancer cell oncogenome: a platform for the development of precision molecular therapies

Open access
Martin, Daniel, Abba, Martin C., Molinolo, Alfredo A., Vitale-Cross, Lynn, Wang, Zhiyong, Zaida, Moraima, Delic, Naomi C., Samuels, Yardena, Lyons, J. Guy, Gutkind, J. Silvio·2014·Oncotarget

Abstract

// Daniel Martin 1 , Martin C. Abba 2 , Alfredo A. Molinolo 1 , Lynn Vitale-Cross 1 , Zhiyong Wang 1 , Moraima Zaida 1 , Naomi C. Delic 4, 5 , Yardena Samuels 3 , J. Guy Lyons 4, 5 , J. Silvio Gutkind 1 1 Oral and Pharyngeal Cancer Branch, National Institutes of Health, Bethesda, USA 2 CINIBA, Facultad de Ciencias Médicas, Universidad Nacional de La Plata, La Plata, Argentina 3 Department of Molecular Cell Biology, The Weizmann Institute of Science, Rehovot, Israel 4 Dermatology, University of Sydney, Camperdown, Australia 5 Cancer Services, Royal Prince Alfred Hospital, Camperdown, Australia Correspondence to: Silvio Gutkind, e-mail: sg39v@nih.gov Keywords: HNSCC, Sequencing, Exome, RNAseq, Cancer Received: July 11, 2014 Accepted: August 28, 2014 Published: November 04, 2014 ABSTRACT The recent elucidation of the genomic landscape of head and neck squamous cell carcinoma (HNSCC) has provided a unique opportunity to develop selective cancer treatment options. These efforts will require the establishment of relevant HNSCC models for preclinical testing. Here, we performed full exome and transcriptome sequencing of a large panel of HNSCC-derived cells from different anatomical locations and human papillomavirus (HPV) infection status. These cells exhibit typical mutations in TP53 , FAT1 , CDK2NA , CASP8 , and NOTCH1 , and copy number variations (CNVs) and mutations in PIK3CA , HRAS , and PTEN that reflect the widespread activation of the PI3K-mTOR pathway. SMAD4 alterations were observed that may explain the decreased tumor suppressive effect of TGF-β in HNSCC. Surprisingly, we identified HPV + HNSCC cells harboring TP53 mutations, and documented aberrant TP53 expression in a subset of HPV + HNSCC cases. This analysis also revealed that most HNSCC cells harbor multiple mutations and CNVs in epigenetic modifiers (e.g., EP300, CREBP, MLL1, MLL2, MLL3, KDM6A, and KDM6B) that may contribute to HNSCC initiation and progression. These genetically-defined experimental HNSCC cellular systems, together with the identification of novel actionable molecular targets, may now facilitate the pre-clinical evaluation of emerging therapeutic agents in tumors exhibiting each precise genomic alteration.

Overview

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.18632/oncotarget.2417

Cites

14 of 14 references verified0 citation errors · 0 not checkable

Statistics

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Show all 14 references

Cited by

See all 204

Metadata

Authors
Martin, D., Abba, M. C., Molinolo, A. A., Vitale-Cross, L., Wang, Z., Zaida, M., Delic, N. C., Samuels, Y., Lyons, J. G., & Gutkind, J. S.
Venue
Oncotarget
Published
2014-10-15
Volume
5
Issue
19
Pages
8906-8923
ISSN
1949-2553 (ISSN-L)
OpenAlex
W2151250097
Cited by
204
References
14
FWCI
14.32
Type
journal article
Language
en
Open access
diamond

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: The head and neck cancer cell oncogenome: a platform for the development of precision molecular therapies. https://app.cochat.ai/papers/10.18632/oncotarget.2417
The paper
Martin, D., Abba, M. C., Molinolo, A. A., Vitale-Cross, L., Wang, Z., Zaida, M., Delic, N. C., Samuels, Y., Lyons, J. G., & Gutkind, J. S. (2014). The head and neck cancer cell oncogenome: a platform for the development of precision molecular therapies. Oncotarget. https://doi.org/10.18632/oncotarget.2417

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.